Streetbeat News

Analyst Ratings

AGL

Benchmark analyst Bill Sutherland has maintained a Buy rating on Agilon Health (NYSE:AGL) but reduced the price target from $28 to $22.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 2:24 pm

VIPS

Benchmark analyst Fawne Jiang has reiterated a Buy rating on Vipshop Holdings (NYSE:VIPS) and maintained a $19 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 2:22 pm

TME

Benchmark analyst Fawne Jiang has reiterated a Buy rating on Tencent Music Entertainment Group (TME) and maintained a $9 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 2:20 pm

CELH

Morgan Stanley analyst Eric Serotta has maintained an Equal-Weight rating on Celsius Holdings (NASDAQ:CELH) but has significantly reduced the price target from $195 to $65.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 2:17 pm

DKNG

Benchmark analyst Mike Hickey has maintained a Buy rating on DraftKings (NASDAQ:DKNG) and increased the price target from $37 to $41.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 2:16 pm

ARMK

Morgan Stanley analyst Toni Kaplan has maintained an Equal-Weight rating on Aramark (NYSE:ARMK) but reduced the price target from $27 to $26.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 2:14 pm

TXN

Benchmark analyst Cody Acree has reiterated a Buy rating on Texas Instruments (NASDAQ:TXN) and maintained a $210 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 2:13 pm

AMP

Morgan Stanley analyst Nigel Dally has maintained an Equal-Weight rating on Ameriprise Financial (AMP) and increased the price target from $360 to $365.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 2:12 pm

AFL

Morgan Stanley analyst Nigel Dally has maintained an Equal-Weight rating on Aflac (NYSE:AFL) and increased the price target from $75 to $80.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 2:11 pm

MIRM

Cantor Fitzgerald analyst Joshua Schimmer has reiterated an Overweight rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and maintained a $50 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 15, 2023 | 2:10 pm